SPIMA Therapeutics, a Montpellier-based startup, has launched with an exclusive global license agreement with SATT AxLR for its lead drug program, SPM001. This peptidic inhibitor targets the Myddosome complex, a crucial component in inflammatory signaling, offering a potential breakthrough for severe immunological disorders and aggressive cancers characterized by MyD88 mutations.
Targeting the Myddosome Complex
The Myddosome is an oligomeric complex essential for transmitting inflammatory signals from TLR/IL1Rs, comprising MyD88 and IRAK family kinases. Its oligomerization depends on OTUD5. SPM001 aims to disrupt this complex, thereby modulating the inflammatory response. SPIMA Therapeutics describes its technology as using "locking peptides into their bioactive α-helical conformation through site-specific introduction of a chemical brace."
Strong Backing and Research Ties
Founded in April 2024, SPIMA Therapeutics has established strong links with the Institute for Regenerative Medicine and Biotherapy (IRMB) and the Institut des Biomolécules Max Mousseron (IBMM). Based at the IHU Immun4cure, a University Hospital Center of Excellence specializing in systemic autoimmune diseases, SPIMA benefits from access to translational and clinical resources. SATT AxLR's President, Philippe Nérin, stated, "This project has benefited from an investment of nearly €1m from SATT AxLR and support from our incubator...SPIMA’s team, combined with our financial and operational resources, has the potential to make a significant impact on patients’ lives."
Potential Impact on Immunological Disorders and Cancers
SPM001 holds promise as a first-in-class treatment for conditions driven by MyD88 mutations. The company emphasizes SPM001's exceptional drug-like properties, positioning it as a potential game-changer in addressing unmet needs in severe immunological disorders and aggressive cancers.
